Ascentage Pharma is a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B and age-related diseases. The company currently has eight programs in phase I-II trials. We focus on developing therapeutics that restore cell apoptosis or inhibit critical tyrosine kinase(s) indicated for specific tumors. Lead asset HQP1351 (3rd generation Bcr-Abl inhibitor) is in pivotal Phase II and aim to submit NDA in 2020. APG-2575 (Bcl-2 selective inhibitor), APG-1252 (Bcl-2/Bcl-xL dual inhibitor), APG-1387 (IAP inhibitor) and APG-115 (MDM2-p53 inhibitor) assets are in Phase I-II development and expecting POC readout in 2020. The company was listed on Hong Kong Stock Exchange in Oct., 2019. We seek global or region partners to co-develop/commercialize our assets.
Hong Kong Stock Exchange
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):